Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Blueprint Mdeicines Coroporation manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This suggests a focused prosecution strategy for their current intellectual property assets, with a single matter requiring active legal attention.
The prosecution is concentrated with 1 distinct examiner and 1 distinct art unit. This structure indicates that the company's current filings are situated within a specific technical niche of the biotechnology sector. A focus on 1 distinct art unit allows for a more streamlined approach to managing examiner communications and expectations, as the practitioner only deals with one set of administrative guidelines.
SASAN, ARADHANA is the busiest examiner for this portfolio. This examiner is responsible for the 1 pending office action currently on record. The outcome of this pending matter will depend entirely on the review conducted by this specific examiner, making their individual prosecution history a key factor for the company.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SASAN, ARADHANA | 1 | 64.6% | +26.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573229 | PHARMACEUTICAL COMPOSITIONS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | SASAN, ARADHANA | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573229 | PHARMACEUTICAL COMPOSITIONS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR | SASAN, ARADHANA | 1615 | §103 | Final Rejection | — | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBlueprint Mdeicines Coroporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Aradhana Sasan has the most, with 1 of Blueprint Mdeicines Coroporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
